Relates to not requiring a prior authorization determination for certain categories of cancer treatments based on National Comprehensive Cancer Network Guidelines.
Impact
The impact of A09407 on state laws could be significant, as it would change how insurance providers approach pre-authorization for cancer care. By removing this barrier, the bill aims to facilitate quicker access to necessary treatments, which is critical for patients facing serious health challenges. The change addresses concerns regarding delayed treatment that can arise from prolonged approval processes, thereby aligning treatment access more closely with clinical needs as determined by established guidelines.
Summary
Bill A09407 aims to amend the insurance law, public health law, and social services law in New York by eliminating the requirement for prior authorization for certain categories of cancer treatments, specifically those categorized as one or two-A by the National Comprehensive Cancer Network (NCCN). The proposed legislation stipulates that insurers and managed care providers cannot require prior authorization for these treatments, potentially streamlining access to timely care for cancer patients. However, while prior authorizations would be waived, medical necessity requirements would still allow insurers to deny claims based on subsequent evaluations.
Conclusion
Overall, A09407 reflects a growing trend towards enhancing healthcare access and reducing bureaucratic hurdles within the insurance system, particularly for critical areas like oncology. Its potential passage could result in a transformative shift in the insurance landscape in New York, impacting both patient outcomes and the operational protocols of insurance providers.
Contention
However, the bill may face contention, primarily from insurance industry stakeholders who may argue that prior authorization serves as a useful check on unnecessary medical expenses. Critics might argue that without proper checks in place, there could be an increase in providers recommending overly expensive treatments that may not be necessary. There may also be concerns about how this change affects the criteria for what constitutes necessary care, especially in terms of insurance reimbursements.
Same As
Relates to not requiring a prior authorization determination for certain categories of cancer treatments based on National Comprehensive Cancer Network Guidelines.
Eliminates the role of the federal centers for disease control and prevention from the determination of policies and practices in the state of New York; directs the use of nationally recognized clinical practice guidelines and best practices.
Requires insurance coverage of sonograms and other diagnostic procedures used to detect breast cancer for covered persons with a prior history of breast cancer or who have a first degree relative with a prior history of breast cancer.
Prior authorization on medications prescribed for antineoplastic cancer treatment prohibition; prior authorization denials based on timing of the provided health care service prohibition; expedited prior authorization review for prescriptions that have previously been authorized or covered requirement
Ensures continuity of care for cancer patients during insurance contract negotiations by requiring insurance coverage and treatment continue until the conclusion of care.
Consolidates all categories of gross income for cross-claiming of net losses and allows 20 year loss carryforward under New Jersey gross income tax; repeals alternate business income calculation.